Arrivo BioVentures focuses on innovative drug development aimed at addressing unmet medical needs across various therapeutic areas, including major depressive disorder and pancreatitis. The company employs a strategic asset selection model that allows it to identify and develop novel drug candidates without being constrained by a specific disease or disorder. This flexibility enables Arrivo to partner with the right commercial entities for each product, enhancing its ability to create a diverse pipeline of late-stage drug candidates that have the potential to be first-in-class or best-in-class.

The company's pipeline includes notable candidates such as SP-624, targeting major depressive disorder, and RABI-767, aimed at severe acute pancreatitis. Arrivo's approach to drug development is characterized by efficiency and thoughtfulness, supported by a team with extensive experience in the field. This unique methodology not only fosters a history of successful product outcomes but also positions Arrivo as a trusted partner for investors and pharmaceutical companies seeking innovative solutions in the healthcare landscape.

United States

At Arrivo, we strive to set a new standard in drug development that starts with the selection of drug candidates and runs throughout clinical development. Our approach and decision-making has delivered a history of excellent returns and product successes that makes us the trusted partner for industry and investors.

Digestive System Diseases

Immune System Diseases

Psychological Diseases

Arrivo BioVentures

Major depressive disorder

SP-624

Pancreatitis

RABI-767

Small Molecule Pharmaceuticals

Inflammatory disease

DLX-2323

Morrisville, North Carolina, United States

North Carolina

Biologics

Therapeutic

Arrivo BioVentures

Company Details